JP2018109004A5 - - Google Patents

Download PDF

Info

Publication number
JP2018109004A5
JP2018109004A5 JP2018008606A JP2018008606A JP2018109004A5 JP 2018109004 A5 JP2018109004 A5 JP 2018109004A5 JP 2018008606 A JP2018008606 A JP 2018008606A JP 2018008606 A JP2018008606 A JP 2018008606A JP 2018109004 A5 JP2018109004 A5 JP 2018109004A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glioma
astrocytoma
grade
adult
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018008606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018109004A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018109004A publication Critical patent/JP2018109004A/ja
Publication of JP2018109004A5 publication Critical patent/JP2018109004A5/ja
Pending legal-status Critical Current

Links

JP2018008606A 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン Pending JP2018109004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647615P 2012-05-16 2012-05-16
US61/647,615 2012-05-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015512776A Division JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065482A Division JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン

Publications (2)

Publication Number Publication Date
JP2018109004A JP2018109004A (ja) 2018-07-12
JP2018109004A5 true JP2018109004A5 (enExample) 2018-09-13

Family

ID=49584234

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Country Status (16)

Country Link
US (3) US10485858B2 (enExample)
EP (4) EP3912634B1 (enExample)
JP (5) JP2015518835A (enExample)
CA (2) CA3183703A1 (enExample)
CY (1) CY1124512T1 (enExample)
DK (1) DK3536334T3 (enExample)
ES (3) ES2967342T3 (enExample)
HR (1) HRP20211432T1 (enExample)
HU (1) HUE056350T2 (enExample)
LT (1) LT3536334T (enExample)
PL (1) PL3536334T3 (enExample)
PT (1) PT3536334T (enExample)
RS (1) RS62406B1 (enExample)
SI (1) SI3536334T1 (enExample)
SM (1) SMT202100545T1 (enExample)
WO (1) WO2013173411A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines
US11712465B2 (en) 2016-10-07 2023-08-01 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
IL296165B2 (en) 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer treatment
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
ES2935702T3 (es) 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
US20210106652A1 (en) * 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
WO2021155501A1 (zh) * 2020-02-05 2021-08-12 瓦克斯恩有限公司 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ATE161190T1 (de) 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US5837231A (en) 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
JP2004353820A (ja) 2003-05-30 2004-12-16 Toyota Motor Corp トリポート型等速ジョイント部品およびトリポート型等速ジョイント
CA2533789C (en) 2003-07-30 2013-09-17 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
JP4926714B2 (ja) 2003-11-19 2012-05-09 サーバック エーピーエス Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
CN101072875B (zh) 2004-12-07 2011-05-18 东丽株式会社 新型癌抗原肽及其用途
DK1853305T3 (en) 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2783700A1 (en) 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
CA2694011C (en) 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US8801711B2 (en) * 2011-06-16 2014-08-12 Clifford T. Solomon Skull clamp system with pressure limiting and alarm systems
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines

Similar Documents

Publication Publication Date Title
Read et al. Glioblastoma microenvironment—from biology to therapy
Barber et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas
US20140120088A1 (en) Agents for the treatment of tumors
Drappatz et al. Therapeutic strategies for inhibiting invasion in glioblastoma
US20160228541A1 (en) Papaya mosaic virus and virus-like particles in cancer therapy
JP6172865B2 (ja) 併用療法によるプロカスパーゼ３活性化
Niedbała et al. Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations
CN101742910A (zh) 治疗脑癌的方法
Kissick et al. The role of active vaccination in cancer immunotherapy: lessons from clinical trials
JP2022130585A5 (enExample)
Monticelli et al. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review
Majd et al. Immunotherapy for neuro-oncology
US11839648B2 (en) Autologous cancer vaccines
EP4054619A1 (en) Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
Moehler et al. New chemotherapeutic strategies in colorectal cancer
KR102256001B1 (ko) 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
JP2024537297A5 (enExample)
CN117980009A (zh) 癌症疗法中的围术期先天性免疫预激
Ursu et al. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma
CN101688205B (zh) 抗肿瘤药物、药剂、组合物及其用途
Parney et al. ATIM-13. Allogeneic tumor lysate/autologous dendritic cell vaccines in newly diagnosed glioblastoma: results of clinical trial MC1272
Lee et al. TRTH-12. Phase 1 safety, pharmacokinetic and imaging study of BLZ-100 tumor paint in pediatric brain tumor patients
Majd et al. for Neuro-oncology
Meninges senting with a CNS tumor. Seizures are more commonly associated with supratentorial than with infratentorial
Weinberg et al. 470 Interim Analysis of a Phase 3 Randomized Controlled Trial of Post-Operative Stereotactic Radiotherapy versus Surgically Targeted Radiation Therapy With GammaTile® for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS, NCT04365374)